Hematology/Oncology

Top Story

Impact of recurrence score assay on chemotherapy receipt varies based on breast cancer risk

August 28, 2015

The use of a 21-gene recurrence score assay appeared associated with greater use of chemotherapy in patients with low-risk breast cancer and a reduced use of chemotherapy in high-risk patients, according to results of a retrospective cohort study of Medicare beneficiaries.

The 21-gene recurrence score assay (Oncotype DX), or RS assay, uses an algorithm based on gene expression to predict the probability of recurrence of hormone-receptive breast cancer and to estimate the benefit of adjuvant chemotherapy. Guidelines recommend physicians consider the use of chemotherapy for patients with early-stage, ER-positive invasive breast cancer, and the 21-gene RS assay may prove cost-effective by prompting more appropriate chemotherapy usage in this population.

In the Journals

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015
Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the chemotherapy drugs after…
In the Journals

Intestinal obstruction a long-term risk for survivors of childhood cancer

August 28, 2015
Survivors of childhood cancer face a long-term risk for intestinal obstruction requiring surgery as a result of their treatment, according to findings from the Childhood…
Erica L. Mayer, MD, MPH In the Journals

Aromatase inhibitors improve recurrence rates, survival in early breast cancer

August 28, 2015
The use of an aromatase inhibitor reduced breast cancer recurrence rates approximately 30% compared with tamoxifen, according to the results of a meta-analysis.Further…
In the Journals

Researchers develop value-based framework for cancer drug pricing

August 27, 2015
Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.“Cancer drug prices have been…
More News Headlines »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan